1. |
Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy[J]. N Engl J Med, 2012, 366(13): 1227-1239. DOI: 10.1056/NEJMra1005073.
|
2. |
Moshfeghi A, Garmo V, Sheinson D, et al. Five-year patterns of diabetic retinopathy progression in US clinical practice[J]. Clin Ophthalmol, 2020, 14: 3651-3659. DOI: 10.2147/OPTH.S275968.
|
3. |
惠延年. 精确评估和控制糖尿病视网膜病变的进展[J]. 中华眼底病杂志, 2021, 37(1): 1-4. DOI: 10.3760/cma.j.cn511434-20201224-00634.Hui YN. Accurate assessment and control of the progression of diabetic retinopathy[J]. Chin J Ocul Fundus Dis, 2021, 37(1): 1-4. DOI: 10.3760/cma.j.cn511434-20201224-00634.
|
4. |
Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group[J]. Ophthalmology, 1991, 98(Suppl 5): S766-785.
|
5. |
Arabi A, Tadayoni R, Ahmadieh H, et al. Update on management of non-proliferative diabetic retinopathy without diabetic macular edema; is there a paradigm shift?[J]. J Ophthalmic Vis Res, 2022, 17(1): 108-117. DOI: 10.18502/jovr.v17i1.10175.
|
6. |
Tomita Y, Lee D, Tsubota K, et al. Updates on the current treatments for diabetic retinopathy and possibility of future oral therapy[J/OL]. J Clin Med, 2021, 10(20): 4666[2021-10-12]. https://pubmed.ncbi.nlm.nih.gov/34682788/. DOI: 10.3390/jcm10204666.
|
7. |
Ashraf H, Lotfi M, Akbari M, et al. Effect of calcium dobesilate on retrobulbar blood flow and choroidal thickness in patients with non-proliferative diabetic retinopathy[J]. Int Ophthalmol, 2021, 41(10): 3479-3486. DOI: 10.1007/s10792-021-01914-x.
|
8. |
Wu R, Wei F, Qu L, et al. Effects of Keluoxin capsule combined with losartan potassium on diabetic kidney disease: study protocol for a randomized double-blind placebo-controlled multicenter clinical trial[J]. Trials, 2020, 21(1): 951. DOI: 10.1186/s13063-020-04852-8.
|
9. |
中国中西医结合学会内分泌专业委员会. 渴络欣胶囊治疗糖尿病肾脏疾病临床应用专家共识[J]. 中国中西医结合杂志, 2020, 40(8): 979-984. DOI: 10.7661/j.cjim.20200225.067.Endocrine Professional Committee of Chinese Society of Integrated Traditional and Western Medicine. Expert consensus on clinical application of Keluoxin Capsule in treating diabetic kidney disease[J]. Chinese Journal of Integrative Medicine, 2020, 40(8): 979-984. DOI: 10.7661/j.cjim.20200225.067.
|
10. |
Yang X, Han X, Wen Q, et al. Protective effect of Keluoxin against diabetic nephropathy in type 2 diabetic mellitus models[J/OL]. Evid Based Complement Alternat Med, 2021, 2021: 8455709[2021-10-19]. https://pubmed.ncbi.nlm.nih.gov/34712350/. DOI: 10.1155/2021/8455709.
|
11. |
Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales[J]. Ophthalmology, 2003, 110(9): 1677-1682. DOI: 10.1016/S0161-6420(03)00475-5.
|
12. |
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation[J]. Diabet Med, 1998, 15(7): 539-553. DOI: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S.
|
13. |
中华医学会眼科学会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2014年)[J]. 中华眼科杂志, 2014, 50(11): 851-865. DOI: 10.3760/cma.j.issn.0412-4081.2014.11.014.Fundus Disease Group, Ophthalmology Society of Chinese Medical Association. Clinical diagnosis and treatment guide of diabetic retinopathy(2014)[J]. Chin J Ophthalmol, 2014, 50(11): 851-865. DOI: 10.3760/cma.j.issn.0412-4081.2014.11.014.
|
14. |
Grading diabetic retinopathy from stereoscopic color fundus photographs-an extension of the modified airlie house classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group[J]. Ophthalmology, 1991, 98(Suppl 5): S786-806.
|
15. |
Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)[J]. Ophthalmologica, 2017, 237(4): 185-222. DOI: 10.1159/000458539.
|
16. |
王平, 景丽, 马秀萍, 等. 磷酸化细胞外信号调节激酶1/2对糖尿病视网膜病变的作用[J]. 中华实验眼科杂志, 2014, 32(11): 989-993. DOI: 10.3760/cma.j.issn.2095-0160.2014.11.006.Wang P, Jing L, Ma XP, et al. A pilot study on phosphorylation of extracellular signal-regulated kinase 1/2-mediated diabetic retinopathy[J]. Chin J Exp Ophthalmol, 2014, 32(11): 989-993. DOI: 10.3760/cma.j.issn.2095-0160.2014.11.006.
|
17. |
罗云, 卢珊, 刘立涛, 等. 渴络欣胶囊对db/db小鼠早期糖尿病视网膜病的防治作用研究[J]. 中国中药杂志, 2019, 44(11): 2324-2330. DOI: 10.19540/j.cnki.cjcmm.20190422.402.Luo Y, Lu S, Liu LT, et al. Preventive and therapeutic effects of Keluoxin capsules on early diabetic retinopathy in db/db mice[J]. China Journal of Chinese Materia Medica, 2019, 44(11): 2324-2330. DOI: 10.19540/j.cnki.cjcmm.20190422.402.
|
18. |
李健, 张晟, 吴建明, 等. 渴络欣含药血清萃取物抑制高糖诱导的大鼠系膜细胞增殖及ERK1/2磷酸化的研究[J]. 四川大学学报(医学版), 2010, 41(5): 780-783. DOI: 10.13464/j.scuxbyxb.2010.05.005.Li J, Zhang S, Wu JM, et al. KeLuoXin medicated serum extract inhibits high glucose-induced proliferation and phosphorylation of ERK1/2 in rat mesangial cell[J]. Journal of Sichuan University (Medical Sciences), 2010, 41(5): 780-783. DOI: 10.13464/j.scuxbyxb.2010.05.005.
|
19. |
Ge N, Kong L, Zhang A, et al. Identification of key lipid metabolites during metabolic dysregulation in the diabetic retinopathy disease mouse model and efficacy of Keluoxin capsule using an UHPLC-MS-based non-targeted lipidomics approach[J]. RSC advances, 2021, 11(1): 5491-5555. DOI: 10.1039/d0ra00343c.
|
20. |
胡金芳, 王玮, 吴建明, 等. 渴络欣胶囊对缺氧诱导视网膜血管新生的抑制作用[J]. 中国实验方剂学杂志, 2014, 20(10): 156-161. DOI: 10.13422/j.cnki.syfjx.2014100156.Hu JF, Wang W, Wu JM, et al. Inhibitory effects of Keluoxin capsule on hypoxia-induced angiogenesis in retina[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2014, 20(10): 156-161. DOI: 10.13422/j.cnki.syfjx.2014100156.
|
21. |
申秀萍, 马娜, 吴建明, 等. 渴络欣胶囊对STZ诱导糖尿病大鼠视网膜病变的防治作用[J]. 中国实验方剂学杂志, 2014, 20(12): 188-192. DOI: 10.13422/j.cnki.syfjx.2014120188.Shen XP, Ma N, Wu JM, et al. Preventive and therapeutical effect of Keluoxin caspsule on diabetic retinopathy rats induced by streptozotocin[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2014, 20(12): 188-192. DOI: 10.13422/j.cnki.syfjx.2014120188.
|
22. |
Luo D, Qin Y, Yuan W, et al. Compound danshen dripping pill for treating early diabetic retinopathy: a randomized, double-dummy, double-blind study[J/OL]. Evid Based Complement Alternat Med, 2015, 2015: 539185[2015-09-20]. https://pubmed.ncbi.nlm.nih.gov/26457110/. DOI: 10.1155/2015/539185.
|
23. |
Tao Y, Jiang P, Liu M, et al. Intravitreal aflibercept partially reverses severe non-proliferative diabetic retinopathy in treatment-naive patients[J/OL]. J Int Med Res, 2021, 49(1): 1220784921[2021-01-01]. https://pubmed.ncbi.nlm.nih.gov/33499698/. DOI: 10.1177/0300060520985369.
|
24. |
Maturi RK, Glassman AR, Josic K, et al. Effect of intravitreous anti-vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: The Protocol W Randomized Clinical Trial[J]. JAMA Ophthalmol, 2021, 139(7): 701-712. DOI: 10.1001/jamaophthalmol.2021.0606.
|
25. |
Fan W, Wang K, Ghasemi FK, et al. Distribution of nonperfusion area on ultra-widefield fluorescein angiography in eyes with diabetic macular edema: DAVE Study[J]. Am J Ophthalmol, 2017, 180: 110-116. DOI: 10.1016/j.ajo.2017.05.024.
|
26. |
Campochiaro PA, Wykoff CC, Shapiro H, et al. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema[J]. Ophthalmology, 2014, 121(9): 1783-1789. DOI: 10.1016/j.ophtha.2014.03.021.
|
27. |
Bonnin S, Dupas B, Lavia C, et al. Anti-vascular endothelial growth factor therapy can improve diabetic retinopathy score without change in retinal perfusion[J]. Retina, 2019, 39(3): 426-434. DOI: 10.1097/IAE.0000000000002422.
|
28. |
Kim J, Moon E, Kwon S. Effect of Astragalus membranaceus extract on diabetic nephropathy[J/OL]. Endocrinol Diabetes Metab Case Rep, 2014, 2014: 140063[2014-09-01]. https://pubmed.ncbi.nlm.nih.gov/25298884/.
|
29. |
Jing D, Bai H, Yin S. Renoprotective effects of emodin against diabetic nephropathy in rat models are mediated via PI3K/Akt/GSK-3beta and Bax/caspase-3 signaling pathways[J]. Exp Ther Med, 2017, 14(5): 5163-5169. DOI: 10.3892/etm.2017.5131.
|
30. |
Zhang J, Xie X, Li C, et al. Systematic review of the renal protective effect of astragalus membranaceus (root) on diabetic nephropathy in animal models[J]. J Ethnopharmacol, 2009, 126(2): 189-196. DOI: 10.1016/j.jep.2009.08.046.
|
31. |
Pang X, Zhang Y, Peng Z, et al. Hirudin reduces nephropathy microangiopathy in STZ-induced diabetes rats by inhibiting endothelial cell migration and angiogenesis[J/OL]. Life Sci, 2020, 255: 117779[2020-08-15]. https://pubmed.ncbi.nlm.nih.gov/32417374/. DOI: 10.1016/j.lfs.2020.117779.
|
32. |
Guo MF, Dai YJ, Gao JR, et al. Uncovering the mechanism of astragalus membranaceus in the treatment of diabetic nephropathy based on network pharmacology[J/OL]. J Diabetes Res, 2020, 2020: 5947304[2020-03-02]. https://pubmed.ncbi.nlm.nih.gov/32215271/. DOI: 10.1155/2020/5947304.
|